1 Market Overview 1.1 Product Overview and Scope of Recurrent Glioblastoma Multiforme Treatment 1.2 Classification of Recurrent Glioblastoma Multiforme Treatment by Type 1.2.1 Overview: Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type: 2017 Versus 2021 Versus 2028 1.2.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type in 2021 1.2.3 AU-105 1.2.4 Axitinib 1.2.5 AXL-1717 1.2.6 AZD-7451 1.2.7 Others 1.3 Global Recurrent Glioblastoma Multiforme Treatment Market by Application 1.3.1 Overview: Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application: 2017 Versus 2021 Versus 2028 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Global Recurrent Glioblastoma Multiforme Treatment Market Size & Forecast 1.5 Global Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast by Region 1.5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region: 2017 VS 2021 VS 2028 1.5.2 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region, (2017-2022) 1.5.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2017-2028) 1.5.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2017-2028) 1.5.5 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2017-2028) 1.5.6 South America Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2017-2028) 1.5.7 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2017-2028) 1.6 Market Drivers, Restraints and Trends 1.6.1 Recurrent Glioblastoma Multiforme Treatment Market Drivers 1.6.2 Recurrent Glioblastoma Multiforme Treatment Market Restraints 1.6.3 Recurrent Glioblastoma Multiforme Treatment Trends Analysis 2 Company Profiles 2.1 Boehringer Ingelheim GmbH 2.1.1 Boehringer Ingelheim GmbH Details 2.1.2 Boehringer Ingelheim GmbH Major Business 2.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.1.4 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.1.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans 2.2 Boston Biomedical, Inc. 2.2.1 Boston Biomedical, Inc. Details 2.2.2 Boston Biomedical, Inc. Major Business 2.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.2.4 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.2.5 Boston Biomedical, Inc. Recent Developments and Future Plans 2.3 Bristol-Myers Squibb Company 2.3.1 Bristol-Myers Squibb Company Details 2.3.2 Bristol-Myers Squibb Company Major Business 2.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.3.4 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.3.5 Bristol-Myers Squibb Company Recent Developments and Future Plans 2.4 Cantex Pharmaceuticals, Inc. 2.4.1 Cantex Pharmaceuticals, Inc. Details 2.4.2 Cantex Pharmaceuticals, Inc. Major Business 2.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.4.4 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.4.5 Cantex Pharmaceuticals, Inc. Recent Developments and Future Plans 2.5 Cavion LLC 2.5.1 Cavion LLC Details 2.5.2 Cavion LLC Major Business 2.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.5.4 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.5.5 Cavion LLC Recent Developments and Future Plans 2.6 Celldex Therapeutics, Inc. 2.6.1 Celldex Therapeutics, Inc. Details 2.6.2 Celldex Therapeutics, Inc. Major Business 2.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.6.4 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.6.5 Celldex Therapeutics, Inc. Recent Developments and Future Plans 2.7 Coherus BioSciences, Inc. 2.7.1 Coherus BioSciences, Inc. Details 2.7.2 Coherus BioSciences, Inc. Major Business 2.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.7.4 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.7.5 Coherus BioSciences, Inc. Recent Developments and Future Plans 2.8 Cortice Biosciences, Inc. 2.8.1 Cortice Biosciences, Inc. Details 2.8.2 Cortice Biosciences, Inc. Major Business 2.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.8.4 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.8.5 Cortice Biosciences, Inc. Recent Developments and Future Plans 2.9 Eisai 2.9.1 Eisai Details 2.9.2 Eisai Major Business 2.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.9.4 Eisai Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.9.5 Eisai Recent Developments and Future Plans 2.10 Eli Lilly and Company 2.10.1 Eli Lilly and Company Details 2.10.2 Eli Lilly and Company Major Business 2.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.10.4 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.10.5 Eli Lilly and Company Recent Developments and Future Plans 2.11 EnGeneIC Ltd 2.11.1 EnGeneIC Ltd Details 2.11.2 EnGeneIC Ltd Major Business 2.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.11.4 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.11.5 EnGeneIC Ltd Recent Developments and Future Plans 2.12 ERC Belgium SA 2.12.1 ERC Belgium SA Details 2.12.2 ERC Belgium SA Major Business 2.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.12.4 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.12.5 ERC Belgium SA Recent Developments and Future Plans 2.13 GenSpera, Inc. 2.13.1 GenSpera, Inc. Details 2.13.2 GenSpera, Inc. Major Business 2.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.13.4 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.13.5 GenSpera, Inc. Recent Developments and Future Plans 2.14 Genzyme Corporation 2.14.1 Genzyme Corporation Details 2.14.2 Genzyme Corporation Major Business 2.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.14.4 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.14.5 Genzyme Corporation Recent Developments and Future Plans 2.15 GW Pharmaceuticals Plc 2.15.1 GW Pharmaceuticals Plc Details 2.15.2 GW Pharmaceuticals Plc Major Business 2.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.15.4 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.15.5 GW Pharmaceuticals Plc Recent Developments and Future Plans 2.16 ImmunoCellular Therapeutics, Ltd. 2.16.1 ImmunoCellular Therapeutics, Ltd. Details 2.16.2 ImmunoCellular Therapeutics, Ltd. Major Business 2.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product and Solutions 2.16.4 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.16.5 ImmunoCellular Therapeutics, Ltd. Recent Developments and Future Plans 3 Market Competition, by Players 3.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022) 3.2 Market Concentration Rate 3.2.1 Top 3 Recurrent Glioblastoma Multiforme Treatment Players Market Share in 2021 3.2.2 Top 10 Recurrent Glioblastoma Multiforme Treatment Players Market Share in 2021 3.2.3 Market Competition Trend 3.3 Recurrent Glioblastoma Multiforme Treatment Players Head Office, Products and Services Provided 3.4 Recurrent Glioblastoma Multiforme Treatment Mergers & Acquisitions 3.5 Recurrent Glioblastoma Multiforme Treatment New Entrants and Expansion Plans 4 Market Size Segment by Type 4.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue and Market Share by Type (2017-2022) 4.2 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast by Type (2023-2028) 5 Market Size Segment by Application 5.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2017-2022) 5.2 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast by Application (2023-2028) 6 North America by Country, by Type, and by Application 6.1 North America Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2028) 6.2 North America Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2028) 6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country 6.3.1 North America Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2028) 6.3.2 United States Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 6.3.3 Canada Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 6.3.4 Mexico Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 7 Europe by Country, by Type, and by Application 7.1 Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2028) 7.2 Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2028) 7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country 7.3.1 Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2028) 7.3.2 Germany Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 7.3.3 France Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 7.3.4 United Kingdom Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 7.3.5 Russia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 7.3.6 Italy Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 8 Asia-Pacific by Region, by Type, and by Application 8.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2028) 8.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2028) 8.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region 8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Region (2017-2028) 8.3.2 China Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 8.3.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 8.3.4 South Korea Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 8.3.5 India Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 8.3.6 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 8.3.7 Australia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 9 South America by Country, by Type, and by Application 9.1 South America Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2028) 9.2 South America Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2028) 9.3 South America Recurrent Glioblastoma Multiforme Treatment Market Size by Country 9.3.1 South America Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2028) 9.3.2 Brazil Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 9.3.3 Argentina Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 10 Middle East & Africa by Country, by Type, and by Application 10.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2028) 10.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2028) 10.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country 10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2028) 10.3.2 Turkey Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 10.3.3 Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 10.3.4 UAE Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2017-2028) 11 Research Findings and Conclusion 12 Appendix 12.1 Methodology 12.2 Research Process and Data Source 12.3 Disclaimer

List of Tables Table 1. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028 Table 2. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028 Table 3. Global Market Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028) Table 4. Global Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) by Region (2017-2022) Table 5. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Region (2023-2028) Table 6. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors Table 7. Boehringer Ingelheim GmbH Major Business Table 8. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 9. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 10. Boston Biomedical, Inc. Corporate Information, Head Office, and Major Competitors Table 11. Boston Biomedical, Inc. Major Business Table 12. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 13. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 14. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors Table 15. Bristol-Myers Squibb Company Major Business Table 16. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 17. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 18. Cantex Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors Table 19. Cantex Pharmaceuticals, Inc. Major Business Table 20. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 21. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 22. Cavion LLC Corporate Information, Head Office, and Major Competitors Table 23. Cavion LLC Major Business Table 24. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 25. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 26. Celldex Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors Table 27. Celldex Therapeutics, Inc. Major Business Table 28. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 29. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 30. Coherus BioSciences, Inc. Corporate Information, Head Office, and Major Competitors Table 31. Coherus BioSciences, Inc. Major Business Table 32. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 33. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 34. Cortice Biosciences, Inc. Corporate Information, Head Office, and Major Competitors Table 35. Cortice Biosciences, Inc. Major Business Table 36. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 37. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 38. Eisai Corporate Information, Head Office, and Major Competitors Table 39. Eisai Major Business Table 40. Eisai Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 41. Eisai Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 42. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors Table 43. Eli Lilly and Company Major Business Table 44. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 45. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 46. EnGeneIC Ltd Corporate Information, Head Office, and Major Competitors Table 47. EnGeneIC Ltd Major Business Table 48. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 49. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 50. ERC Belgium SA Corporate Information, Head Office, and Major Competitors Table 51. ERC Belgium SA Major Business Table 52. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 53. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 54. GenSpera, Inc. Corporate Information, Head Office, and Major Competitors Table 55. GenSpera, Inc. Major Business Table 56. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 57. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 58. Genzyme Corporation Corporate Information, Head Office, and Major Competitors Table 59. Genzyme Corporation Major Business Table 60. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 61. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 62. GW Pharmaceuticals Plc Corporate Information, Head Office, and Major Competitors Table 63. GW Pharmaceuticals Plc Major Business Table 64. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 65. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 66. ImmunoCellular Therapeutics, Ltd. Corporate Information, Head Office, and Major Competitors Table 67. ImmunoCellular Therapeutics, Ltd. Major Business Table 68. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product and Solutions Table 69. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 70. Global Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022) Table 71. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players (2019, 2020, 2021, and 2022) Table 72. Breakdown of Recurrent Glioblastoma Multiforme Treatment by Company Type (Tier 1, Tier 2 and Tier 3) Table 73. Recurrent Glioblastoma Multiforme Treatment Players Head Office, Products and Services Provided Table 74. Recurrent Glioblastoma Multiforme Treatment Mergers & Acquisitions in the Past Five Years Table 75. Recurrent Glioblastoma Multiforme Treatment New Entrants and Expansion Plans Table 76. Global Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) by Type (2017-2022) Table 77. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Type (2017-2022) Table 78. Global Recurrent Glioblastoma Multiforme Treatment Revenue Forecast by Type (2023-2028) Table 79. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2022) Table 80. Global Recurrent Glioblastoma Multiforme Treatment Revenue Forecast by Application (2023-2028) Table 81. North America Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2022) & (USD Million) Table 82. North America Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2023-2028) & (USD Million) Table 83. North America Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2022) & (USD Million) Table 84. North America Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2023-2028) & (USD Million) Table 85. North America Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2022) & (USD Million) Table 86. North America Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2023-2028) & (USD Million) Table 87. Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2022) & (USD Million) Table 88. Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2023-2028) & (USD Million) Table 89. Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2022) & (USD Million) Table 90. Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2023-2028) & (USD Million) Table 91. Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2022) & (USD Million) Table 92. Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2023-2028) & (USD Million) Table 93. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2022) & (USD Million) Table 94. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2023-2028) & (USD Million) Table 95. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2022) & (USD Million) Table 96. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2023-2028) & (USD Million) Table 97. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Region (2017-2022) & (USD Million) Table 98. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Region (2023-2028) & (USD Million) Table 99. South America Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2022) & (USD Million) Table 100. South America Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2023-2028) & (USD Million) Table 101. South America Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2022) & (USD Million) Table 102. South America Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2023-2028) & (USD Million) Table 103. South America Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2022) & (USD Million) Table 104. South America Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2023-2028) & (USD Million) Table 105. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2017-2022) & (USD Million) Table 106. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Type (2023-2028) & (USD Million) Table 107. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2017-2022) & (USD Million) Table 108. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Application (2023-2028) & (USD Million) Table 109. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2017-2022) & (USD Million) Table 110. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Country (2023-2028) & (USD Million) List of Figures Figure 1. Recurrent Glioblastoma Multiforme Treatment Picture Figure 2. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type in 2021 Figure 3. AU-105 Figure 4. Axitinib Figure 5. AXL-1717 Figure 6. AZD-7451 Figure 7. Others Figure 8. Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application in 2021 Figure 9. Hospital Picture Figure 10. Clinic Picture Figure 11. Others Picture Figure 12. Global Recurrent Glioblastoma Multiforme Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028 Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Revenue and Forecast (2017-2028) & (USD Million) Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Region (2017-2028) Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Region in 2021 Figure 16. North America Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 17. Europe Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 18. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 19. South America Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 20. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 21. Recurrent Glioblastoma Multiforme Treatment Market Drivers Figure 22. Recurrent Glioblastoma Multiforme Treatment Market Restraints Figure 23. Recurrent Glioblastoma Multiforme Treatment Market Trends Figure 24. Boehringer Ingelheim GmbH Recent Developments and Future Plans Figure 25. Boston Biomedical, Inc. Recent Developments and Future Plans Figure 26. Bristol-Myers Squibb Company Recent Developments and Future Plans Figure 27. Cantex Pharmaceuticals, Inc. Recent Developments and Future Plans Figure 28. Cavion LLC Recent Developments and Future Plans Figure 29. Celldex Therapeutics, Inc. Recent Developments and Future Plans Figure 30. Coherus BioSciences, Inc. Recent Developments and Future Plans Figure 31. Cortice Biosciences, Inc. Recent Developments and Future Plans Figure 32. Eisai Recent Developments and Future Plans Figure 33. Eli Lilly and Company Recent Developments and Future Plans Figure 34. EnGeneIC Ltd Recent Developments and Future Plans Figure 35. ERC Belgium SA Recent Developments and Future Plans Figure 36. GenSpera, Inc. Recent Developments and Future Plans Figure 37. Genzyme Corporation Recent Developments and Future Plans Figure 38. GW Pharmaceuticals Plc Recent Developments and Future Plans Figure 39. ImmunoCellular Therapeutics, Ltd. Recent Developments and Future Plans Figure 40. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players in 2021 Figure 41. Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021 Figure 42. Global Top 3 Players Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in 2021 Figure 43. Global Top 10 Players Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in 2021 Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022) Figure 45. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Type in 2021 Figure 46. Global Recurrent Glioblastoma Multiforme Treatment Market Share Forecast by Type (2023-2028) Figure 47. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Application in 2021 Figure 48. Global Recurrent Glioblastoma Multiforme Treatment Market Share Forecast by Application (2023-2028) Figure 49. North America Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type (2017-2028) Figure 50. North America Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application (2017-2028) Figure 51. North America Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Country (2017-2028) Figure 52. United States Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 53. Canada Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 54. Mexico Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 55. Europe Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type (2017-2028) Figure 56. Europe Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application (2017-2028) Figure 57. Europe Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Country (2017-2028) Figure 58. Germany Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 59. France Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 60. United Kingdom Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 61. Russia Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 62. Italy Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 63. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type (2017-2028) Figure 64. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application (2017-2028) Figure 65. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Region (2017-2028) Figure 66. China Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 67. Japan Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 68. South Korea Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 69. India Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 70. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 71. Australia Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 72. South America Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type (2017-2028) Figure 73. South America Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application (2017-2028) Figure 74. South America Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Country (2017-2028) Figure 75. Brazil Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 76. Argentina Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 77. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type (2017-2028) Figure 78. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application (2017-2028) Figure 79. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Country (2017-2028) Figure 80. Turkey Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 81. Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 82. UAE Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 83. Methodology Figure 84. Research Process and Data Source

Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Cantex Pharmaceuticals, Inc. Cavion LLC Celldex Therapeutics, Inc. Coherus BioSciences, Inc. Cortice Biosciences, Inc. Eisai Eli Lilly and Company EnGeneIC Ltd ERC Belgium SA GenSpera, Inc. Genzyme Corporation GW Pharmaceuticals Plc ImmunoCellular Therapeutics, Ltd.